How were Metacrine's earnings last quarter?

Metacrine, Inc. (NASDAQ:MTCR) announced its quarterly earnings results on Thursday, May, 13th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.06.

What other stocks do shareholders of Metacrine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Metacrine investors own include Bridgewater Bancshares (BWB) , Bank of Commerce (BOCH) , Blink Charging (BLNK) , Bloomin' Brands (BLMN) , Bausch Health Companies (BHC) , Bridge Bancorp (BDGE) , Bank of America (BAC) , AXIS Capital (AXS) , Avadel Pharmaceuticals (AVDL) and Blue Apron (APRN) .

When did Metacrine IPO?

Metacrine (MTCR) raised $84 million in an initial public offering (IPO) on Wednesday, September 16th 2020. The company issued 6,500,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

NASDAQ:MTCR

Metacrine (MTCR) Stock Price, News & Analysis

→ Special FREE offer on stock hotsheets (From DTI) (Ad)

Free MTCR Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.58
▼
$0.59
50-Day Range: $0.55
▼
$0.59
52-Week Range: $0.30
▼
$0.59

Volume: 83,889 shs
Average Volume: 225,834 shs
Market Capitalization: $24.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Metacrine alerts:

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Metacrine Stock (NASDAQ:MTCR)

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Ad DTI

This company has increased its dividend every year for 54 years

Click here to get them (for Free).

MTCR Stock News Headlines

April 17, 2024 | reuters.com

US says China is boosting Russia's war machine in Ukraine

December 20, 2023 | bbc.com

Twitter says hackers downloaded private account data

April 19, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

November 9, 2023 | morningstar.com

AN2 Therapeutics Inc ANTX

July 8, 2023 | morningstar.com

Beijing Huafeng Test & Control Technology Co Ltd Class A

July 3, 2023 | nbcnews.com

3 children among 9 dead as Russian missile slams into pizza restaurant

March 31, 2023 | abcnews.go.com

Gun Control

March 21, 2023 | usnews.com

Gun Control And Gun Rights

April 19, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

March 20, 2023 | nbcnews.com

Major Russian missile barrage slams targets across Ukraine

March 15, 2023 | bbc.co.uk

Dnipro missile: Son in search of his mother

March 9, 2023 | thestreet.com

How Elon Musk Controls Tesla With Only a Minority Ownership Stake

February 24, 2023 | forbes.com

Old Tax Regime Vs. New Tax Regime: Which Is Better In 2023?

December 23, 2022 | finance.yahoo.com

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement

November 17, 2022 | finanznachrichten.de

Metacrine, Inc.: Metacrine Reports Third-Quarter 2022 Results

November 15, 2022 | finance.yahoo.com

Metacrine Reports Third-Quarter 2022 Results

October 11, 2022 | marketscreener.com

METACRINE, INC. : Other Events (form 8-K) - Marketscreener.com

September 28, 2022 | finance.yahoo.com

Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis - Yahoo Finance

September 25, 2022 | benzinga.com

Lifshitz Law PLLC Announces Investigations of TALO, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equilli - Benzinga

September 22, 2022 | benzinga.com

Lifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equilli - Benzinga

September 21, 2022 | marketwatch.com

Lifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - MarketWatch

September 19, 2022 | prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR - PR Newswire

September 17, 2022 | benzinga.com

Lifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equillium (NASDAQ:EQ) - Benzinga

September 8, 2022 | benzinga.com

METACRINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Metacrine Inc. - MTCR

September 7, 2022 | globenewswire.com

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates STR, MNRL, EQ, MTCR - GlobeNewswire

September 7, 2022 | benzinga.com

Apexigen, Inc. - Common Stock (APGN), (AQST), (ATIP), (ATXI), Cardiff Oncology, Inc. - Common Stock (CRDF - Benzinga

September 7, 2022 | finance.yahoo.com

Equillium to Acquire Metacrine in All-Stock Transaction - Yahoo Finance

See More Headlines

Receive MTCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/13/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MTCR
CUSIP: N/A
CIK: 1634379
Web: www.metacrine.com
Phone: 858-369-7800
Fax: N/A
Employees: 10
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,210,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -84.88%
Return on Assets: -59.33%

Debt

Debt-to-Equity Ratio: 0.34
Current Ratio: 12.15
Quick Ratio: 12.15

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.36 per share
Price / Book: 0.43

Miscellaneous

Outstanding Shares: 42,570,000
Free Float: 36,695,000
Market Cap: $24.75 million
Optionable: Not Optionable
Beta: -0.73

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. David M. Maggio (Age 64)
Chief Bus. Officer, Pres, CEO, Sec., Treasurer, Principal Financial & Acct. Officer

Key Competitors

View All Competitors

MTCR Stock Analysis - Frequently Asked Questions

How were Metacrine's earnings last quarter?: Metacrine, Inc. (NASDAQ:MTCR) announced its quarterly earnings results on Thursday, May, 13th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.06.
What other stocks do shareholders of Metacrine own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Metacrine investors own include Bridgewater Bancshares (BWB), Bank of Commerce (BOCH), Blink Charging (BLNK), Bloomin' Brands (BLMN), Bausch Health Companies (BHC), Bridge Bancorp (BDGE), Bank of America (BAC), AXIS Capital (AXS), Avadel Pharmaceuticals (AVDL) and Blue Apron (APRN).
When did Metacrine IPO?: Metacrine (MTCR) raised $84 million in an initial public offering (IPO) on Wednesday, September 16th 2020. The company issued 6,500,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

This page (NASDAQ:MTCR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Metacrine (MTCR) Stock Price, News & Analysis

About Metacrine Stock (NASDAQ:MTCR)

MTCR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

MTCR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info